How tenofovir disoproxil fumarate can impact on solubility and dissolution rate of efavirenz?

被引:15
|
作者
Bazzo, Giovana Carolina [1 ]
Mostafa, Dina [1 ]
Franca, Maria Terezinha [1 ]
Pezzini, Bianca Ramos [1 ]
Stulzer, Hellen Karine [1 ]
机构
[1] Univ Fed Santa Catarina, Programa Posgrad Farm, Campus Trindade, BR-88040970 Florianopolis, SC, Brazil
关键词
Efavirenz; Tenofovir disoproxil fumarate; Solubility; Dissolution; Eutectic mixture; DRUG-DELIVERY SYSTEM; SOLID FORMS; ENHANCEMENT; CYCLODEXTRIN; MECHANISMS; BEHAVIOR; DESIGN;
D O I
10.1016/j.ijpharm.2019.118597
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Efavirenz (EFZ) and tenofovir disoproxil fumarate (TDF) can be used simultaneously in the treatment of human immunodeficiency virus type1 infection. In this work the impact of TDF, a hydrophilic drug, on the solubility and dissolution rate of EFZ, a poorly water-soluble drug, was evaluated. EFZ/TDF binary mixtures in different molar ratios were prepared. Differential scanning calorimetry (DSC) results indicate the formation of a eutectic mixture, the molar ratio of 65/35 being the eutectic point. It was observed an increase in the EFZ solubility in water and acidic conditions (0.1 N HCl and biorelevant medium), in the presence of TDF. On the other hand, there was a decreasing on EFZ solubility in phosphate buffer pH 6.8, probably influenced by the lower solubility of TDF in this medium. The high solubility of TDF in water and acidic medium may have contributed to improve the solubility of EFZ, as well as the formation of a eutectic mixture, supported by X-ray powder diffraction (XRPD) and Fourier Transform infrared spectroscopy (FTIR) analyses. However, TDF solubility and dissolution rate was not significantly influenced by the presence of EFZ.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen
    Mathias, Anita A.
    Hinkle, John
    Menning, Mark
    Hui, James
    Kaul, Sanjeev
    Kearney, Brian P.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 46 (02) : 167 - 173
  • [2] Impact of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide on psychiatric symptoms and neurocognition
    Vergori, Alessandra
    Del Duca, Giulia
    Lorenzini, Patrizia
    Brita, Anna Clelia
    Mastrorosa, Ilaria
    Fusto, Marisa
    Camici, Marta
    Ottou, Sandrine
    Gagliardini, Roberta
    Paulicelli, Jessica
    De Zottis, Federico
    Grilli, Elisabetta
    Esvan, Rozenn
    Plazzi, Maria Maddalena
    Mazzotta, Valentina
    Bellagamba, Rita
    Antinori, Andrea
    Pinnetti, Carmela
    AIDS, 2025, 39 (03) : 270 - 275
  • [3] Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects
    Ramanathan, Srini
    Custodio, Joseph M.
    Wei, Xuelian
    Wang, Hui
    Fordyce, Marshall
    Dave, Ami
    Ling, Kah Hiing J.
    Szwarcberg, Javier
    Kearney, Brian P.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (03) : 281 - 288
  • [4] Simultaneous Spectrophotometric Estimation of Tenofovir Disoproxil Fumarate and Lamivudine in Three Component Tablet Formulation Containing Efavirenz
    Sharma, R.
    Mehta, K.
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 72 (04) : 527 - 530
  • [5] RP-HPLC method for simultaneous estimation of lamivudine, tenofovir disoproxil fumarate and efavirenz in tablet formulation
    Anandakumar, K.
    Abirami, G.
    Murugan, S.
    Ashok, B.
    JOURNAL OF ANALYTICAL CHEMISTRY, 2013, 68 (09) : 815 - 821
  • [6] RP-HPLC method for simultaneous estimation of lamivudine, tenofovir disoproxil fumarate and efavirenz in tablet formulation
    K. Anandakumar
    G. Abirami
    S. Murugan
    B. Ashok
    Journal of Analytical Chemistry, 2013, 68 : 815 - 821
  • [7] Pharmaceutical cocrystals of Efavirenz: Towards the improvement of solubility, dissolution rate and stability
    Gowda, B. H. Jaswanth
    Nechipadappu, Sunil Kumar
    Shankar, S. J.
    Chavali, Murthy
    Paul, Karthika
    Ahmed, Mohammed Gulzar
    Sanjana, A.
    Shanthala, H. K.
    MATERIALS TODAY-PROCEEDINGS, 2022, 51 : 394 - 402
  • [8] Simultaneous Estimation of Lamivudine, Tenofovir Disoproxil Fumarate and Efavirenz in Bulk and Tablet Dosage Form by Cramer's Rule
    Baravkar, Atul
    Santosh, Gandhi
    Namrata, Bawaskar
    Chopade, Vitthal
    Puri, Makarand
    Neharkar, Vishnu
    Kale, Ramdas
    Kature, Dattatray
    Jadhav, Rahul
    Patil, Manisha
    Devkate, Reshma
    Jain, Alfa
    Kadam, Deepali
    Khedkar, Amol
    Vijapure, Sachin
    Wani, Nilima
    Shinde, Ganesh
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2023, 13 (03) : 582 - 587
  • [9] The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz
    Asif, Sumbul
    Baxevanidi, Evangelia
    Hill, Andrew
    Venter, Willem Daniel Francois
    Fairlie, Lee
    Masenya, Masebole
    Serenata, Celicia
    Sokhela, Simiso
    Chandiwana, Nomathemba
    AIDS, 2021, 35 : S117 - S125
  • [10] Pharmacokinetics of fixed-dose combination of tenofovir disoproxil fumarate, lamivudine, and efavirenz: results of a randomized, crossover, bioequivalence study
    Abhyankar, Dhiraj
    Shedage, Ashish
    Gole, Milind
    Raut, Preeti
    INTERNATIONAL JOURNAL OF STD & AIDS, 2017, 28 (05) : 491 - 498